Sign Out
Vaccines: No data are available on the response to live or inactivated vaccines. Live vaccines should not be given concurrently with tildrakizumab (see Precautions).
Interactions with cytochrome P450: Concomitant medicinal products affecting tildrakizumab pharmacokinetics are not expected since it is cleared from the body by general protein catabolism processes with no contribution of cytochrome P450 (CYP450) enzymes, and it is not eliminated by renal or hepatic pathways. Furthermore, tildrakizumab does not impact the pharmacokinetics of concomitant medicinal products metabolised by CYP450 enzymes either through direct or indirect mechanisms (see Pharmacology: Pharmacokinetics under Actions).
Interactions with other immunosuppressive agents or phototherapy: The safety and efficacy of tildrakizumab in combination with other immunosupressive agents, including biologics, or phototherapy has not been evaluated.
Continue with Google